Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
This is a study to evaluate the efficacy and safety of the addition of ertugliflozin to metformin monotherapy in Asian participants with Type 2 diabetes mellitis (T2DM) who have inadequate glycemic control on metformin…
- Trial name
- NCT02630706
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Metformin
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin.
- Trial name
- NCT02036515
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Metformin
- Volunteers
- 464 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.
- Trial name
- NCT00147758
- Testing
- Colesevelam hydrochloride
- Where
- 47 sites in United States, Mexico and 1 more
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo
Short Sleep
Sleep Extension for Metabolic Health
The study aims to examine the effects of a sleep extension intervention on the metabolic and cardio-vascular profile of obese people who present traditional diabetes risk factors, and who are habitually sleep deprived.
- Trial name
- NCT04467268
- Testing
- Sleep extension
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Diabetes Mellitus, Type 2
12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
The objective is to investigate the efficacy, safety and pharmacokinetics of three different doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control.
- Trial name
- NCT00789035
- Testing
- BI 10773, metformin
- Where
- 74 sites in Argentina, Croatia and 11 more
- Volunteers
- 408 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
This study is a multicenter, randomized, double-blind, placebo-controlled , phase 3 clinical trial aimed at evaluating the efficacy and safety of HDM1005 versus placebo in subjects with T2DM inadequate glycemic control with diet…
- Trial name
- NCT07394114
- Testing
- HDM1005 1, HDM1005 2
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and DPP-4 inhibitor in Japanese patients with type 2 diabetes mellitus.
- Trial name
- NCT01242228
- Testing
- ipragliflozin, DPP-4 inhibitor
- Where
- 6 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
The purpose of this study is to assess the efficacy of omarigliptin 25 mg weekly (as monotherapy) compared with sitagliptin 50 mg daily and placebo, and the long term safety (up to 52 weeks) of omarigliptin 25 mg weekly.
- Trial name
- NCT01703221
- Testing
- Omarigliptin, Sitagliptin
- Volunteers
- 414 people
- Sponsor
- Merck Sharp & Dohme LLC
Vitamin D Deficiency, Rotator Cuff Tears
Vitamin D3 Supplementation for Vitamin D Deficiency in Rotator Cuff Repair Surgery
Rotator cuff injuries are the most common cause of shoulder disability and is increasingly more prevalent in the aging population.
- Trial name
- NCT05009498
- Testing
- Vitamin D3 supplementation
- Where
- 2 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Community Memorial Health System
Type 2 Diabetes Mellitus
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and…
- Trial name
- NCT02564211
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.
- Trial name
- NCT00722371
- Testing
- Sitagliptin phosphate, Pioglitazone hydrochloride, Metformin
- Volunteers
- 1,615 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)
The objective of this study is to evaluate the efficacy on glycemic variability and safety of gemigliptin 50 mg orally administered once daily for 12 weeks compared with Dapagliflozin 10mg in patients with type 2 diabetes…
- Trial name
- NCT03202563
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg, Diet/exercise questionnaire
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- LG Chem
Type 2 Diabetes Mellitus
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
This two-phase study was to examine if 16 weeks of treatment with sitagliptin in combination with atorvastatin reduces hemoglobin A1C (A1C) and low density lipoprotein cholesterol (LDL-C) from baseline more than atorvastatin…
- Trial name
- NCT01477853
- Testing
- Sitagliptin, Atorvastatin, Metformin (open-label)
- Volunteers
- 166 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
This study will evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in participants with Type 2 diabetes mellitus with Stage 3 Chronic Kidney Disease (CKD) who have inadequate glycemic control on background…
- Trial name
- NCT01986855
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg
- Volunteers
- 468 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
WelChol® and Insulin in Treating Patients With Type 2 Diabetes
The purpose of the study is to see how safe and effective and tolerable the use of WelChol® is for type 2 diabetes when added to insulin alone or in combination with other anti-diabetic drugs
- Trial name
- NCT00151749
- Testing
- Colesevelam hydrochloride
- Where
- 47 sites in United States, Mexico and 1 more
- Volunteers
- 260 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably > 1500 mg metformin in patients with…
- Trial name
- NCT00622284
- Testing
- BI 1356, Glimepiride
- Where
- 221 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,560 people
- Sponsor
- Boehringer Ingelheim
Hypercholesterolemia
A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors.
- Trial name
- NCT07404553
- Testing
- SHR-1918 Injection
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Diabetes Mellitus, Type 2
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30…
- Trial name
- NCT01183013
- Testing
- Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg
- Where
- 132 sites in United States, Estonia and 4 more
- Volunteers
- 936 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）
This multicenter, randomized, double-Blind, parallel-group, placebo-controlled phase III trial is to evaluate the efficacy and safety of UBT251 Injection in patients with Type 2 Diabetes Mellitus with inadequate glycemic control…
- Trial name
- UNIGUIDE-1 (NCT07659574)
- Testing
- UBT251 Injection 2.0 mg, UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg
- Where
- China
- Volunteers
- 360 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Type 2 Diabetes Mellitus
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to…
- Trial name
- NCT02551874
- Testing
- Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin
- Where
- 40 sites in United States, Czechia and 8 more
- Volunteers
- 650 people
- Sponsor
- AstraZeneca